Legend Biotech Corporation
LEGN
$27.75
$1.063.97%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 70.28% | 38.54% | 115.04% | 134.56% | 66.60% |
| Total Other Revenue | -93.59% | -99.88% | -97.30% | 446.34% | 1,378.95% |
| Total Revenue | 69.99% | 36.74% | 107.52% | 134.73% | 66.86% |
| Cost of Revenue | 51.30% | 20.37% | 11.28% | 29.12% | 8.37% |
| Gross Profit | 376.19% | 150.64% | 135.30% | 113.92% | 121.27% |
| SG&A Expenses | 9.75% | 23.28% | 28.99% | 33.25% | 61.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.96% | 21.20% | 15.98% | 30.40% | 22.29% |
| Operating Income | 38.24% | 47.87% | 57.03% | 38.08% | 23.96% |
| Income Before Tax | 67.68% | -594.48% | -65.80% | 127.59% | -93.43% |
| Income Tax Expenses | -86.11% | 157.52% | 35,620.00% | 813.49% | 1,639.93% |
| Earnings from Continuing Operations | 68.33% | -589.05% | -68.78% | 118.15% | -101.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.33% | -589.05% | -68.78% | 118.15% | -101.46% |
| EBIT | 38.24% | 47.87% | 57.03% | 38.08% | 23.96% |
| EBITDA | 40.00% | 49.78% | 57.76% | 39.09% | 22.95% |
| EPS Basic | 68.56% | -583.63% | -67.18% | 118.00% | -99.53% |
| Normalized Basic EPS | 67.90% | -588.78% | -61.38% | 130.38% | -91.54% |
| EPS Diluted | 67.83% | -580.90% | -67.18% | 117.98% | -99.53% |
| Normalized Diluted EPS | 67.90% | -588.78% | -61.38% | 127.65% | -91.54% |
| Average Basic Shares Outstanding | 0.74% | 0.84% | 0.97% | 0.82% | 0.96% |
| Average Diluted Shares Outstanding | 0.74% | 0.84% | 0.97% | 10.77% | 0.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |